A bispecific anti-fluorescein x anti-CD3 T-cell engager in combination with fluoresceinated adaptors enables lysis of AML cells
{{output}}
Tumor-targeting antibodies, antibody-drug conjugates, and radionuclide antibody conjugates are established therapeutic tools in clinical use. Beyond, bispecific T-cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T-cells are becoming clinical... ...
